Understanding Hallucinations (Part II)

Status Recruiting

Clinical Trial Summary

Rationale: Hallucinations occur in many patients with different kinds of diseases, including psychiatric, neurological and perceptual impairment. The origin of these hallucinations is only partly understood. This prevents correct prediction of treatment response and hampers the development of new, more effective treatment strategies.

Different subtypes of hallucinations resulting from different neuropathology may exist across diagnostic entities, and be responsive to different treatment strategies. Understanding the origin of these subtypes with use of fMRI and EEG can help to make rational treatment decisions on an individual basis and enhance the development of innovative treatment paradigms.

Objective: The primary objective is to find specific abnormalities on resting state fMRI related to the pathophysiology of different subtypes of hallucinations. Secondary objectives are to find EEG connectivity measures that are related to the pathophysiology of different subtypes of hallucinations, reveal correlating patterns of EEG and fMRI that underlie the experience of hallucinations across different disorders, and to examine the frequency of spontaneous synchronized burst activations in auditory and visual cortices using fMRI.

Study design: The investigators intend to examine neural correlates of hallucinations over different disorders using resting state EEG, fMRI and sMRI in an observational study.

Study population: A total of 140 hallucinating patients will be included, 20 of each of the 7 different diagnostic groups. As a control group, 140 non-hallucinating patients with the same disorder of similar severity will be included.

Main study parameters/endpoints: The main study endpoint is the difference in resting state correlates as measured with fMRI between hallucinating and non-hallucinating participants and between hallucinating individuals of different subtypes, namely: connectivity within the DMN and connectivity of the DMN to sensory cortices and the hippocampal-amygdala complex.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participation in the study will entail an MRI scan of 40 minutes and an EEG measurement of 5 minutes. Total visit time, including preparations, will be approximately 2,5 hours. The risks associated with participation and the benefits to the individuals are negligible. The potential benefit to society in the future is considerable if the findings lead to optimization of treatment strategies and treatment response.

Clinical Trial Description

n/a

Study Design

Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Hallucinations

Clinical Trial Details

NCT number	NCT02460965
Study type	Observational
Source	UMC Utrecht
Contact	Sanne Koops, Msc.
Phone	+31887558672
Email	S.Koops@umcutrecht.nl
Status	Recruiting
Phase	N/A
Start date	November 2013
Completion date	March 2017

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Completed	`NCT04990414` - Cognitive Behaviour Therapy for Voices and Dissociation	Phase 2
Completed	`NCT01373866` - Multimodal MRI-guided rTMS to Treat Refractory Hallucinations	N/A
Recruiting	`NCT04352569` - Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia	N/A
Completed	`NCT00087542` - Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug	Phase 2
Recruiting	`NCT01907568` - Understanding Hallucinations (Part I)	N/A
Completed	`NCT00701909` - Pain Medicine for Wound Care Procedures	Phase 3
Completed	`NCT00042159` - Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations	N/A
Recruiting	`NCT05210062` - Impact of Closely Grouped, Iterative Exposures to Suxamethonium During ECT on the Sensitization to NMBA and the Development of Protective Antibodies
Completed	`NCT00288340` - Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging	N/A
Not yet recruiting	`NCT06208176` - HD-tDCS for Hallucinations	N/A
Completed	`NCT00308997` - Transcranial Magnetic Stimulation for "Voices"	Phase 2
Completed	`NCT02974400` - Evaluation of Internet-based Cognitive Behavioral Self-help Treatments for People With Psychosis	N/A
Recruiting	`NCT04399096` - Sound and Vision: A Collaboration Between Service-users, Artists and the Public to Explore the Lived Experience of Hallucinations
Completed	`NCT00328952` - Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Patients With Schizophrenia	N/A
Completed	`NCT05240339` - Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Understanding Hallucinations (Part II) — UH-2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms